Shukra Pharmaceuticals Share Price

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	7.27	39.95	7.59	6.50	14.74
Total Income Growth (%)	-81.80	426.35	16.76	-55.88	27.13
Total Expenses	6.63	12.84	7.11	4.86	6.89
Total Expenses Growth (%)	-48.34	80.64	46.31	-29.55	-6.13
EBIT	0.64	27.11	0.48	1.64	7.84
EBIT Growth (%)	-97.64	0.00	-70.59	-79.04	84.66
Profit after Tax (PAT)	-1.72	20.36	2.38	1.03	5.39
PAT Growth (%)	-108.43	756.34	130.41	-80.84	70.22
EBIT Margin (%)	8.80	67.87	6.37	25.28	53.21
Net Profit Margin (%)	-23.60	50.97	31.33	15.88	36.55
Basic EPS (₹)	-0.04	0.47	0.05	0.02	0.12

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	7.25	39.95	7.59	6.50	14.74
Total Income Growth (%)	-81.85	426.35	16.75	-55.88	27.13
Total Expenses	6.62	12.84	7.11	4.86	6.89
Total Expenses Growth (%)	-48.40	80.64	46.24	-29.51	-6.13
EBIT	0.63	27.11	0.48	1.64	7.84
EBIT Growth (%)	-97.69	0.00	-70.54	-79.07	84.65
Profit after Tax (PAT)	-1.73	20.36	2.38	1.03	5.39
PAT Growth (%)	-108.48	756.34	130.95	-80.88	70.22
EBIT Margin (%)	8.63	67.87	6.37	25.25	53.21
Net Profit Margin (%)	-23.82	50.97	31.33	15.84	36.55
Basic EPS (₹)	-0.04	0.47	0.05	0.02	0.12

	FY 2026
Total Revenue	61.31
Total Revenue Growth (%)	-
Total Expenses	32.53
Total Expenses Growth (%)	-
Profit after Tax (PAT)	22.06
PAT Growth (%)	-
Operating Profit Margin (%)	52.67
Net Profit Margin (%)	38.88
Basic EPS (₹)	0.50

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	61.29	36.79	77.39	60.03	20.57
Total Revenue Growth (%)	66.58	-52.46	28.91	191.88	78.03
Total Expenses	32.52	23.46	57.50	55.59	19.55
Total Expenses Growth (%)	38.63	-59.21	3.45	184.36	73.63
Profit after Tax (PAT)	22.05	9.58	18.54	4.41	0.75
PAT Growth (%)	130.26	-48.35	320.68	486.99	2,116.79
Operating Profit Margin (%)	52.66	42.75	27.04	8.02	6.36
Net Profit Margin (%)	38.88	29.38	24.85	7.48	3.66
Basic EPS (₹)	0.50	0.22	16.93	26.21	4.79

All figures in Rs Cr, unless mentioned otherwise

Insights

PAT: Slipping to Red
Company has posted a loss of Rs 1.72 cr in Mar 31, 2026 quarter after 3 consecutive quarter of profits. (Source: Consolidated Financials)
Quarterly Topline Performance
Company witnessed QoQ revenue decline of 81.85%, which is lowest in the last 3 years. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2026
Total Assets	117.44
Total Assets Growth (%)	-
Total Liabilities	27.59
Total Liabilities Growth (%)	-
Total Equity	89.85
Total Equity Growth (%)	-
Current Ratio (x)	3.63
Total Debt to Equity (x)	0.06
Contingent Liabilities	0.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	117.41	86.77	77.84	74.97	35.11
Total Assets Growth (%)	35.31	11.47	3.83	113.53	1.01
Total Liabilities	27.58	23.93	20.20	49.67	18.76
Total Liabilities Growth (%)	15.25	18.47	-59.33	164.77	-2.09
Total Equity	89.83	62.84	57.64	25.30	16.35
Total Equity Growth (%)	42.95	9.02	127.83	54.74	4.81
Current Ratio (x)	3.63	3.79	3.97	1.25	1.27
Total Debt to Equity (x)	0.06	0.07	0.05	0.20	0.21
Contingent Liabilities	0.00	1.40	1.40	1.40	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026
Net Cash flow from Operating Activities	3.93
Net Cash used in Investing Activities	-14.14
Net Cash flow from Financing Activities	4.07
Net Cash Flow	-6.14
Closing Cash & Cash Equivalent	5.98
Closing Cash & Cash Equivalent Growth (%)	-
Total Debt/ CFO (x)	1.28

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	3.15	7.92	-5.20	3.17	7.78
Net Cash used in Investing Activities	-14.18	-1.26	-1.20	-4.43	-1.53
Net Cash flow from Financing Activities	4.83	-4.52	12.41	4.94	-6.68
Net Cash Flow	-6.20	2.14	6.01	3.68	-0.42
Closing Cash & Cash Equivalent	5.92	12.12	9.98	3.97	0.09
Closing Cash & Cash Equivalent Growth (%)	-51.18	21.41	151.20	4,552.34	-79.18
Total Debt/ CFO (x)	1.59	0.53	-0.61	1.60	0.43

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 3.93 cr is 0.18 times compared to the reported net profit of Rs 22.06 cr. (Source: Consolidated Financials)
Increase in Cash from Investing
Company has used Rs 14.18 cr for investing activities which is an YoY increase of 1021.96%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026
Return on Equity (%)	24.55
Return on Capital Employed (%)	31.67
Return on Assets (%)	18.78
Interest Coverage Ratio (x)	30.49
Asset Turnover Ratio (x)	-
Price to Earnings (x)	60.24
Price to Book (x)	14.79
EV/EBITDA (x)	39.84
EBITDA Margin (%)	58.74

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	24.54	15.23	32.16	17.41	4.59
Return on Capital Employed (%)	31.66	20.04	31.66	14.54	5.73
Return on Assets (%)	18.77	11.03	23.81	5.87	2.13
Interest Coverage Ratio (x)	30.47	28.47	77.96	23.36	10.35
Asset Turnover Ratio (x)	0.56	0.40	0.98	1.07	0.59
Price to Earnings (x)	60.61	100.00	19.31	4.17	12.61
Price to Book (x)	14.79	15.23	6.20	0.73	0.58
EV/EBITDA (x)	39.86	56.02	15.78	2.97	4.30
EBITDA Margin (%)	58.73	51.97	29.79	11.15	14.48

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Shukra Pharma	61.50	15.11	24.55	31.67	18.78	0.70	52.67	38.88	0.50	3.63	0.06	1.28
Kwality Pharmaceutic	36.03	7.36	20.31	27.62	11.37	25.54	20.13	13.38	64.90	1.80	0.39	7.87
NGL Fine Chem	36.25	5.29	14.61	17.15	8.82	21.81	13.54	9.60	77.90	1.84	0.33	2.50
Lincoln Pharma	14.52	1.68	11.60	14.96	9.87	9.66	17.38	13.09	43.88	5.25	0.01	0.04
Fermenta Biotech	13.86	2.51	17.86	22.88	11.20	15.11	19.13	13.37	24.70	1.86	0.27	1.17
Add More

Annual Ratios (%)

Choose from Peers

Bajaj Healthcare
Themis Medicare
Wanbury Ltd
Bharat Parenterals
Kopran Ltd

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Shukra Pharma Stock Performance	-2.79	-3.91	-6.57	-17.25	119.87	1082.44	1505.18
Kwality Pharmaceutic Stock Performance	2.99	39.08	47.68	64.17	146.49	664.49	2227.31
NGL Fine Chem Stock Performance	5.57	24.82	24.81	20.17	117.03	84.97	70.37
Lincoln Pharma Stock Performance	2.81	-3.99	4.97	3.13	5.83	44.66	94.76
Fermenta Biotech Stock Performance	0.26	17.39	8.69	5.77	16.29	133.70	10.22
Add More

Category	No. of Shares	Percentage
Promoters	22,31,35,600	50.96 %
Pledge	0	0.00 %
Others	21,47,43,840	49.04 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	50.96	50.96	50.96	50.96
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	49.04	49.04	49.04	49.04

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Others
Jun 05, 2026
Board Meeting
Audited Results & Final Dividend
May 08, 2026
Final
1%
May 08, 2026

Board Meetings

Announced on	Meeting on
Jun 05, 2026	Jun 10, 2026
Others
May 08, 2026	May 07, 2026
Audited Results & Final Dividend
Mar 06, 2026	Mar 16, 2026
Others
Jan 30, 2026	Feb 04, 2026
Quarterly Results
Oct 31, 2025	Nov 13, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Jun 04, 2025 Sep 18, 2025 1%
May 29, 2024 Sep 23, 2024 10%
May 29, 2023 Sep 15, 2023 5%
May 30, 2022 Sep 22, 2022 5%
May 08, 2026 - 1%
Bonus
Announced on Ex-Date
Feb 29, 2024 Apr 19, 2024
Bonus Ratio: 3 share(s) for every 1 shares held
Splits
Announced on Ex-Date
Jan 29, 2025 Mar 21, 2025
Split: Old FV10.0| New FV:1.0
Rights
Announced on Ex-Date
Aug 25, 2022 Feb 02, 2023
Rights ratio: 6 share for every 1 held at a price of Rs 20.0
AGM/EGM Meetings
Announced on Meeting on
Dec 03, 2025 Jan 05, 2026
-
Oct 07, 2025 Nov 01, 2025
-
Sep 15, 2025 Sep 30, 2025
-
Feb 04, 2025 Mar 10, 2025
-
Sep 20, 2024 Sep 30, 2024
Rs.1.0000 per share(10%)Final Dividend & A.G.M.

Announced on	Ex-Date	Dividend%
Jun 04, 2025	Sep 18, 2025	1%
May 29, 2024	Sep 23, 2024	10%
May 29, 2023	Sep 15, 2023	5%
May 30, 2022	Sep 22, 2022	5%
May 08, 2026	-	1%

Announced on	Ex-Date
Feb 29, 2024	Apr 19, 2024
Bonus Ratio: 3 share(s) for every 1 shares held

Announced on	Ex-Date
Jan 29, 2025	Mar 21, 2025
Split: Old FV10.0\| New FV:1.0

Announced on	Ex-Date
Aug 25, 2022	Feb 02, 2023
Rights ratio: 6 share for every 1 held at a price of Rs 20.0

Announced on	Meeting on
Dec 03, 2025	Jan 05, 2026
-
Oct 07, 2025	Nov 01, 2025
-
Sep 15, 2025	Sep 30, 2025
-
Feb 04, 2025	Mar 10, 2025
-
Sep 20, 2024	Sep 30, 2024
Rs.1.0000 per share(10%)Final Dividend & A.G.M.

About Shukra Pharma

Shukra Pharmaceuticals Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 1,356.55 Crore) operating in Pharmaceuticals sector.

Shukra Pharmaceuticals Ltd. key Products/Revenue Segments include Commission, Pharmaceuticals and Sale of services for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 7.27 Crore, down 81.80 % from last quarter Total Income of Rs 39.95 Crore and down 50.65 % from last year same quarter Total Income of Rs 14.74 Crore. Company has reported net profit after tax of Rs -1.72 Crore in latest quarter.

The company’s top management includes Mr.Dakshesh Rameshchandra Shah, Mrs.Anar Jayeshbhai Patel, Mr.Dhruvin Shah, Mr.Sanskruti Jayeshbhai Patel, Mrs.Shital Shah, Mrs.Payal Sujay Mehta, Mrs.Bhoomiben Patel, Mr.Jitendra Somchand Shah, Mrs.Pinki Nirmal Sagar, Mrs.Ritu Kapoor, Mr.Sarjeevan Singh Rathore, Mrs.Sonal Deepalbhai Gandhi, Mrs.Anar Jayesh Patel, Ms.Arpita Kabra. Company has B J Trivedi & Associates as its auditors. As on 31-03-2026, the company has a total of 43.79 Crore shares outstanding.

Shukra Pharma Share Price Today is Rs. 30.98. On previous day, the Shukra Pharma Share Price (NSE) closed at Rs. 31.87, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 50.96% of the stake in Shukra Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Shukra Pharma stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Shukra Pharma shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Shukra Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Shukra Pharma Dividend: Ever since 1993, Shukra Pharma dividends has been paid out around 8 times. As on 09 Jun, 2026, 03:50 PM IST, The overall dividend yield for Shukra Pharma stands at 0.03%. The last dividend paid was on September 18, 2025 (Rs. 0.01). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 0.5.

Shukra Pharma Bonus: The most recent bonus issue had been in year April 19, 2024 around 2 years ago at 1 : 3 ratio. The first bonus issue was announced in Feb 2024.

Stock Forecast:
After showing 7.27 Cr. of sales and 81.8% of quarterly net loss, there have been multiple ups and downs in the Shukra Pharma stock prices in the past few weeks. For example, Shukra Pharma stock price on 2nd of June 2026 was around Rs. 29.12. Shukra Pharma share price now stands at an average of Rs. 30.98. Judging by last week's performance, stock is in up trend.

Shukra Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Shukra Pharma share.

Historical Prices and Performance:
Shukra Pharma, incorporated in 1993 is a Small Cap company (with a market cap of Rs. 1356.55) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Shukra Pharma stock was 24.55%, 15.23%, 32.16%, 17.41% and 4.59% respectively.
The Shukra Pharma share gave a 3 year return of 638.94% as compared to Nifty 50 which gave a return of 25.2%.
Shukra Pharma announced 1.0% final dividend on September 18, 2025.

Key Metrics:
PE Ratio of Shukra Pharma is 63.26
Prices/Sales Ratio of Shukra Pharma is 23.42
Price/Book Ratio of Shukra Pharma is 15.55

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 63.26 and 15.55 respectively.

Leadership of Shukra Pharma :
Arpita Kabra is Co. Secretary & Compl. Officer
Anar Jayesh Patel is Chief Financial Officer
Dakshesh Rameshchandra Shah is Managing Director
Payal Sujay Mehta is Executive Director
Dhruvin Shah is Whole Time Director
Sanskruti Jayeshbhai Patel is Whole Time Director
Anar Jayeshbhai Patel is Whole Time Director
Shital Shah is Whole Time Director
Bhoomiben Patel is Independent Director
Sonal Deepalbhai Gandhi is Independent Director
Sarjeevan Singh Rathore is Independent Director
Jitendra Somchand Shah is Independent Director
Pinki Nirmal Sagar is Independent Director
Ritu Kapoor is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

3rd Floor, Dev House,Opp. WIAA Office,Judges Bungalows Road,Ahmedabad, Gujarat - 380054

Contact

info@shukrapharmaceuticals.com

http://www.shukrapharmaceuticals.com

PE Ratio(x)	61.50
EPS - TTM(₹)	0.50
MCap(₹ Cr.)	1,356.55
MCap Rank	86
PB Ratio(x)	15.55
Div Yield(%)	0.03
Face Value(₹)	1.00
52W High(₹)	65.26
52W Low(₹)	12.97
MCap/Sales	23.42
Beta(1 Month)	-
BV/Share(₹)	2.05

1 Day	-2.79%
1 Month	-7.63%
3 Months	-27.28%
1 Year	116.04%
3 Years	638.94%
5 Years	1866.98%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Shukra Pharmaceuticals Share Price

Key Metrics

Shukra Pharma share price insights

Shukra Pharma Share Price Returns

Shukra Pharma Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Shukra Pharma Top Searches

Corporate Actions

About Shukra Pharma

Executive Leadership

Auditors

FAQs about Shukra Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News